Skip to content

A clinical trial to evaluate Xiaoaiping injection's effects on the peripheral platelet and its parameters in patients under chemotherapy.

A clinical trial to evaluate Xiaoaiping injection's effects on the peripheral platelet and its parameters in patients under chemotherapy

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-13003888
Enrollment
Unknown
Registered
2013-11-22
Start date
2013-12-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer?Gastric cancer

Interventions

Xiao‘aiping parenteral solution group:Xiao'aiping parenteral solution + The basal treatment
Control:Xiao'aiping parenteral solution + The basal treatment

Sponsors

Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: The case inclusion criteria are as follows: 1. imaging and / or histological or cytological diagnosis of lung cancer (non-small cell lung cancer) or gastric cancer; 2. No restriction of age or sex; 3. quality of life: KPS score >=60 points; 4. expected survival >=6 months; 5. have indications of chemotherapy and did not receive radiotherapy or chemotherapy within two months; 6. platelet count less than 400*10^9/L; 7. no other serious diseases combined (heart, liver, kidney, blood disease); 8. volunteer to participate in clinical trial, and signed informed consent.

Exclusion criteria

Exclusion criteria: Cases with one of the following conditions will be excluded: 1. Do not meet the above inclusion criteria; 2. mental disorders (cancer combined with moderate or severe depression), can not properly express subjective symptoms; 3. severe uncontrolled medical illness or acute infections that need antibiotics treatment; 4. pregnant or lactating women; 5. history of poor medication adherence in previous treatment.

Design outcomes

Primary

MeasureTime frame
PLT;MPV;PCT;PD;

Secondary

MeasureTime frame
Hgb;RBC;WBC;NEUT;AST;LDH;CK;ALP;ALT;GPT;STB;CB;Cr;BUN;UA;PT;APTT;TT;Fbg;DD;CEA;CYFRA21-1;SCC;NSE;CA125;CA15-3;CA19-9;CA72-4;GL;

Countries

China

Contacts

Public ContactXinyi Chen

Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine

chenxinyi0729@126.com+86 010 84013127

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026